




# ETHICAL ASPECTS OF MEDICAL RESEARCH INVOLVING HUMAN BEINGS



ds Eric Koster MA

# MEDICAL RESEARCH INVOLVING HUMAN BEINGS: AN ATTEMPT AT A DEFINITION



- ‘The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments)...’

(Declaration of Helsinki, General Principles art. 6)

- This type of research always subjects human beings to specific treatments or dictates rules of conduct to them

(Dutch Law on Medical Research Involving Human Beings’)

# THE NEED FOR ASSESSMENT OF MEDICAL RESEARCH INVOLVING HUMAN BEINGS

- **1900: Walter Reed and the transmission of yellow fever:**
  - taking risks which nowadays would be considered unacceptable
- **1932 – 1972: The Tuskegee experiment:**
  - no informed consent
  - withholding of available treatment
  - taking advantage of a vulnerable population
  - causing severe damage and even death



# THE NEED FOR ASSESSMENT OF MEDICAL RESEARCH INVOLVING HUMAN BEINGS

## WW II: Nazi Experiments on Concentration Camp inmates and prisoners of war:

In 1942 SS-physicians start medical experiments on POW's in Dachau to find the best way to rewarm pilots who have ditched in ice-cold seawater. Of the 300 POW's involved about 90 die



Cold water immersion experiment on a POW wearing an experimental Luftwaffe garment



In the concentration-camp Auschwitz SS-physician Joseph Mengele carries out genetic experiments on 1500 twins he personally selects on the 'Rampe' Only 200 children survive


Surviving twins on the day of their liberation by the Red Army



# THE NUREMBERG CODE (1946)


## ART. 1:

**‘The voluntary consent of the human subject is absolutely essential.** This means that the person involved should have legal capacity to give consent; should be so situated as to be able to exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and comprehension of the elements of the subject matter involved as to enable him to make an understanding and enlightened decision.’



# THE 'SOFTENON-SCANDAL'

- In 1961 public opinion around the world is shocked by the Thalidomide-scandal. 2000 children die, 10.000 are seriously disfigured.
- Authorities are demanded to take action and make regulatory arrangements to oversee the testing of medicines



# THE HELSINKI DECLARATION (1964)


- A set of 'Ethical principles for Medical Research Involving Human Subjects' adopted by the World Medical Association
- Widely regarded as the cornerstone document of human research ethics
- Constantly updated




The screenshot shows the official WMA website page for the Declaration of Helsinki. The header includes the WMA logo and navigation links in English, Spanish, and French. A 'Members' Area' button is visible in the top right. The main navigation bar lists 'Home', 'What we do', 'Publications', 'Media', 'Events', 'About us', 'Education', and 'JDN'. Below this, a breadcrumb trail reads 'WMA Home > Publications > Policies'. The left sidebar contains a 'Policies' section with links to 'About', 'Archives', 'Council Resolutions', 'World Medical Journal', 'Medical Ethics Manual', 'WMA DoH 1964-2014', 'White Papers', 'Background Documents', 'Toolkits', 'CPW Book', 'Speaking Books', and 'Videos'. The main content area is titled 'WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects'. It includes social media sharing options (Print, PDF, Send, Follow, Vind ik leuk) and a search bar. The text states: 'Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 29th WMA General Assembly, Tokyo, Japan, October 1975; 35th WMA General Assembly, Venice, Italy, October 1983; 41st WMA General Assembly, Hong Kong, September 1989; 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; 52nd WMA General Assembly, Edinburgh, Scotland, October 2000; 53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of Clarification added); 55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added); 59th WMA General Assembly, Seoul, Republic of Korea, October 2008; 64th WMA General Assembly, Fortaleza, Brazil, October 2013'.

# SELFREGULATION FAILS

- The Nuremberg Code and the Declaration of Helsinki lead to the development of standards, protocols and the instrument of the Randomised Controlled Trial (RCT)
- Self-regulation is not always succesful




Henry Beecher: 'Ethics and Clinical Research'  
New England Journal of Medicine, 1966





# LAWS AND REGULATIONS


The Directive 'Good Clinical Practice' (1996) and the European Directives Clinical Trials on Medicinal Products for Human Use (2001, 2003, 2005 and april 2014)



The Netherlands: *Wet Medisch-wetenschappelijk Onderzoek met mensen* (1998)

# THE FOUR GUIDING PRINCIPLES IN WESTERN MEDICAL ETHICS ('GEORGETOWN MANTRA')

- **Autonomy:**
  - to respect the autonomy of the participant or of the participant's representative
- **Beneficence:**
  - to act always in the best interest of the participant
- **Non-maleficence:**
  - to do as little harm as possible to the participant
- **Justice:**
  - to act fairly by all men



# THE FOUR GUIDING PRICIPLES IN WESTERN MEDICAL ETHICS

## ORIGIN


- The principles of **Beneficence** and **Non Maleficence** have their roots in the **Hippocratic tradition**. They lead to questions like:
  - who benefits from the experiment?
  - what is the risk/benefit ratio?

**‘In dubio abstine!  
Primum non nocere!’**



- **Respect for the autonomy of the participants** has its roots in the tradition of the **Enlightenment**. It involves:
  - the absence of force or coercion and
  - the obtaining of informed consent

**‘Have the courage to make up your own mind!’**



# A CLOSER LOOK: BENEFICENCE THERAPEUTIC EFFECT?

- **Non-Therapeutic experiment:**
  - No therapeutic effect on participants is intended  
(f.e. Phase I trials)
- **Therapeutic experiment:**
  - Aims at therapeutic effect on participants  
(f.e. Phase III trials - but what about the controlgroup in a placebo-controlled Phase III trial?)





# A CLOSER LOOK: MALEFICENCE UNSOUND RESEARCH



- Methodically unsound: design unfit to test the hypothesis
- Dangerous: causes damage to the participants
- No qualified personnel available
- Logistics and equipment of the studycentre insufficient
- Preliminary investigations insufficient (laboratory research, research on animals, study of literature)

# A CLOSER LOOK: MALEFICENCE RISKS

- **Physical:**
  - side-effects
  - interference with other treatments
- **Psychological:**
  - depression
  - suicide
- **Social:**
  - genetic information
  - stigmatisation
- **Economic:**
  - hospitalisation
  - insurance problems



# A CLOSER LOOK: MALEFICENCE BURDENS AND INCONVENIENCES

- **Investment of time:**

- how many hours must a participant invest in the trial?
- what is the length of the inclusion period?

- **Hospital visits:**

- how many?
- out-clinic or hospitalisation?

- **Rules of conduct:**

- influence on daily rhythm and/or diet
- medication
- keeping diaries etcetera

- **Choices:**

- do participants see themselves confronted with difficult choices?



# A CLOSER LOOK: AUTONOMY

## INFORMED CONSENT ON THE BASIS OF FULL INFORMATION

- The aim of the experiment
- The reason why the participant is asked to participate
- The importance of the experiment
- The obligations of the participant
- The burden that is laid on the participant (and the inconveniences)
- The risks involved for the participant
- Any measures that are taken to contain those risks
- Compensation in money (if there is any)
- Insurance
- The confidentiality of collected data





# A CLOSER LOOK: AUTONOMY

## INFORMED CONSENT ON THE BASIS OF FULL INFORMATION

- The right to refuse to be included without repercussions on subject treatment
- The right to withdraw at any time (without giving an explanation) without repercussions on participant treatment
- Identity of the investigator and information on how to reach her/him
- Opportunity to ask questions and consult an independent physician
- The opportunity to consult family, acquaintances or one's own General Practitioner



# A CLOSER LOOK: AUTONOMY

## EXTRA DEMANDS IN CASE PARTICIPANTS ARE UNDER AGE OR UNABLE TO EXPRESS THEIR WISHES

- All participants (or the group of patients they belong to as a whole) must benefit directly from the experiment
- Burden and risks must be minimised
- Prior to inclusion a procedure must be agreed upon to determine expressions of refusal from the side of the participants
- Subject must be represented by a next of kin who gives written consent



# A CLOSER LOOK: JUSTICE

- Fair selection of participants (male/female; age-groups)
- No exploitation of vulnerable populations (cf. Tuskegee, underdeveloped countries)



- Research Ethics Committees only have the right to make comments on the soundness and reasonability of a study-protocol. REC's are not allowed to make comments on the desirability of any specific trial

# To CONCLUDE

- The instrument of the Randomised Clinical Trials and the assessment of trial protocols by Research Ethics Committees guarantee *up to a certain extent* that medical research involving human beings is conducted in a sound, careful and responsible way
- *up to a certain extent*:
  - Assessment will always remain necessary. As long as it makes sense to ask the question ‘This is our practice, but is it a good practice?’ there will be reason for ethical debate...
- As the following example makes clear:



# THE CONSTANT NEED FOR ASSESSMENT OF MEDICAL RESEARCH INVOLVING HUMAN BEINGS

**2008: The Pro Patria Probiotics trial in Utrecht, The Netherlands**  
**Devastating judgment by the Health Care Inspectorate:**

## **ALMOST EVERYTHING WENT WRONG!**

inadequate study-design; investigators not experienced enough; trial not conducted conform GCP; inadequate monitoring; inadequate information; in some cases no informed consent; Data Safety Monitoring Committee not satisfactorily informed: consequently a late discovery of significant higher mortality in the studygroup as compared to the controlgroup; etcetera

